CSIR-NIIST Develops Technology To Convert Biomedical Waste Into Soil Additives

THIRUVANANTHAPURAM: CSIR-National Institute for Interdisciplinary Science and Technology (NIIST) in Thiruvananthapuram has developed a technology that converts pathogenic biomedical waste into value-added soil additives that eliminate the need for costly and energy-intensive incineration.

The rig will be installed and commissioned at a function at AIIMS, New Delhi on Monday. The rig ensures the safe disposal of waste materials such as blood, urine, sputum and laboratory disposables while simultaneously imparting a pleasant fragrance to the treated material.

The prototype has a daily processing capacity of 400 kg, with an initial capacity to handle 10 kg of degradable medical waste per day. Once validated and approved by competent authorities, the technology will be ready for full-scale implementation in healthcare facilities across the country.

India generates approximately 743 tonnes of biomedical waste daily, according to the 2023 annual report of the Central Pollution Control Board (CPCB). Traditional disposal methods, including incineration and open dumping, pose serious health and environmental risks, including the release of carcinogenic pollutants, particulate matter and ash residues.

SOURCE : The Indian Express

Related Posts

  • Pharma
  • May 31, 2025
  • 52 views
Generic drugs can bring hope for SMA patients’

Dr Ann Agnes Mathew, a consultant paediatric neurologist and neuromuscular specialist based in Bengaluru, treats nearly 600 SMA patients from across India. In an interview with DH’s Udbhavi Balakrishna, she…

  • Pharma
  • May 31, 2025
  • 59 views
47% of pharma MOUs from VGGS 2024 commissioned

Gandhinagar:  The state govt said that 47% of MoUs signed in the pharmaceutical sector in the Vibrant Gujarat Global Summit (VGGS) 2024 have been commissioned. It said on Friday that…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Generic drugs can bring hope for SMA patients’

Generic drugs can bring hope for SMA patients’

47% of pharma MOUs from VGGS 2024 commissioned

47% of pharma MOUs from VGGS 2024 commissioned

I-Sec downgrades Aurobindo Pharma to Add, target price Rs 1,330

I-Sec downgrades Aurobindo Pharma to Add, target price Rs 1,330

AstraZeneca gets CDSCO nod for lung cancer drug

AstraZeneca gets CDSCO nod for lung cancer drug